Skip to main content
SpringerLink
Log in

Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases

  • Protocol
  • First Online:
Book cover Human Monoclonal Antibodies

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1060))

Abstract

Monoclonal antibodies (mAbs) are antibodies of a single antigen specificity produced by identical immune cells, i.e., clones of a common germ cell. They offer unprecedented opportunities to drug development because of their ability to target almost any cell surface or secreted molecule with remarkable efficacy and safety. In this chapter, the application of human mAbs in the treatment of inflammatory diseases is reviewed. We discuss in detail several mAb-based drugs such as anti-tumor necrosis factor (anti-TNF), anti-interleukin-1 (anti-IL-1) receptor, anti-IL-6 receptor, anti-α4 integrin subunit, and anti-CD20 agents, all of which have been documented by clinical trials to be efficacious and have been approved for the therapy of several inflammatory and immune diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, spondyloarthropathies, juvenile arthritis, psoriasis, psoriatic arthritis, and others. These novel drugs can be used either as a monotherapy or in combination with other conventional therapeutic modalities, particularly if the disease under treatment is refractory to therapy using solely conventional techniques. As a large variety of mAb-based agents targeting a plethora of cytokines, chemokines, adhesion and co-stimulatory molecules, receptors, as well as diverse cell types, are presently under investigation, the therapeutic armamentarium of the clinician is expected to greatly broaden in the near future, providing improved patient care for a wide range of devastating diseases of our times.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497

    Article  PubMed  Google Scholar 

  2. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317

    Article  CAS  PubMed  Google Scholar 

  3. Siegel DL (2002) Recombinant monoclonal antibody technology. Transfus Clin Biol 9:15–22

    Article  CAS  PubMed  Google Scholar 

  4. Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312:643–646

    Article  CAS  PubMed  Google Scholar 

  5. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851–6855

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH (1985) A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314:268–270

    Article  CAS  PubMed  Google Scholar 

  7. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554

    Article  CAS  PubMed  Google Scholar 

  8. Lonberg N, Huszar D (1995) Human antibodies from transgenic mice. Int Rev Immunol 13:65–93

    Article  CAS  PubMed  Google Scholar 

  9. Andreakos E, Taylor PC, Feldmann M (2002) Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Biotechnol 13:615–620

    Article  CAS  PubMed  Google Scholar 

  10. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 334:244–247

    Article  Google Scholar 

  11. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025–4031

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784–9788

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196

    Article  CAS  PubMed  Google Scholar 

  14. Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364–371

    Article  CAS  PubMed  Google Scholar 

  15. Elliott MJ, Maini RN, Feldmann M et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681–1690

    Article  CAS  PubMed  Google Scholar 

  16. Van den Brande JM, Braat H, van den Brink GR et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124:1774–1785

    Article  PubMed  CAS  Google Scholar 

  17. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125–1127

    Article  CAS  PubMed  Google Scholar 

  18. Elliott MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105–1110

    Article  CAS  PubMed  Google Scholar 

  19. Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–1939

    Article  CAS  PubMed  Google Scholar 

  20. Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343:1594–1602

    Article  CAS  PubMed  Google Scholar 

  21. Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34:334–342

    Article  CAS  PubMed  Google Scholar 

  22. Sander O, Rau R, van Riel P et al (1996) Neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for three months: results of a European phase II trial. Arthritis Rheum 39:S242

    Google Scholar 

  23. Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141–147

    Article  CAS  PubMed  Google Scholar 

  24. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259

    Article  CAS  PubMed  Google Scholar 

  25. Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB (2001) Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 60:660–669

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA (2002) Efficacy of a novel PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41:1133–1137

    Article  CAS  Google Scholar 

  27. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104

    Article  CAS  PubMed  Google Scholar 

  28. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF (2011) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 15:1–278

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rémy A, Avouac J, Gossec L, Combe B (2011) Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 29:96–103

    PubMed  Google Scholar 

  30. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ES, Fry-Smith A (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev CD007649

    Google Scholar 

  31. Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B (2011) Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 38:835–845

    Article  CAS  PubMed  Google Scholar 

  32. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70:266–271

    Article  CAS  PubMed  Google Scholar 

  33. Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, Blosche C, Landay A, Moreland LW, Pope RM (1996) Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 39:257–265

    Article  CAS  PubMed  Google Scholar 

  34. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43:1001–1009

    Article  CAS  PubMed  Google Scholar 

  35. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614–624

    Article  CAS  PubMed  Google Scholar 

  36. Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20:259–262

    CAS  PubMed  Google Scholar 

  37. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T (1998) Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 20:247–259

    Article  CAS  PubMed  Google Scholar 

  38. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE (1994) Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 37:992–999

    Article  CAS  PubMed  Google Scholar 

  39. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE (1996) A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 23:1338–1344

    CAS  PubMed  Google Scholar 

  40. Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE (1997) Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 40:849–853

    Article  CAS  PubMed  Google Scholar 

  41. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65:1006–1012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Navarro-Millán I, Singh JA, Curtis JR (2012) Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 34:788–802

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Gout T, Ostör AJ, Nisar MK (2011) Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 30:1471–1474

    Article  PubMed  Google Scholar 

  44. Singh JA, Beg S, Lopez-Olivo MA (2011) Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 38:10–20

    Article  PubMed  PubMed Central  Google Scholar 

  45. Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ (2011) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 50:552–562

    Article  CAS  Google Scholar 

  46. Shaw T, Quan J, Totoritis MC (2003) B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 62(suppl 2):ii55–ii59

    Google Scholar 

  47. Maloney DG, Grillo-López AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195

    Article  CAS  PubMed  Google Scholar 

  48. Scott SD (1998) Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin’s lymphoma. Cancer Pract 6:195–197

    Article  CAS  PubMed  Google Scholar 

  49. Buch MH, Smolen JS, Betteridge N et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909–920

    Article  CAS  PubMed  Google Scholar 

  50. Tak PP, Kalden JR (2011) Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 13(Suppl 1):S5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Bukhari M, Abernethy R, Deighton C et al (2011) BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 50:2311–2313

    Article  Google Scholar 

  52. Eccles SA (2001) Monoclonal antibodies targeting cancer: “magic bullets” or just the trigger? Breast Cancer Res 3:86–90

    Article  CAS  PubMed  Google Scholar 

  53. Choy EH, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS (1992) Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 36:291–298

    Article  CAS  PubMed  Google Scholar 

  54. Kirkham BW, Thien F, Pelton BK, Pitzalis C, Amlot P, Denman AM, Panayi GS (1992) Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 19:1348–1352

    CAS  PubMed  Google Scholar 

  55. Olsen NJ, Brooks RH, Cush JJ, Lipsky PE, St Clair EW, Matteson EL, Gold KN, Cannon GW, Jackson CG, McCune WJ, Fox DA, Nelson B, Lorenz T, Strand V (1996) A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum 39:1102–1108

    Article  CAS  PubMed  Google Scholar 

  56. Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, St Clair EW, Schnitzer TJ, Johnston JM (1996) CAMPATH-1H in rheumatoid arthritis—an intravenous dose-ranging study. Br J Rheumatol 35:231–240

    Article  CAS  PubMed  Google Scholar 

  57. Choy EH, Connolly DJ, Rapson N, Jeal S, Brown JC, Kingsley GH, Panayi GS, Johnston JM (2000) Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) 39:1139–1146

    Article  CAS  Google Scholar 

  58. Veale DJ, Reece RJ, Parsons W, Radjenovic A, O’Connor PJ, Orgles CS, Berry E, Ridgway JP, Mason U, Boylston AW, Gibbon W, Emery P (1999) Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. Ann Rheum Dis 58:342–349

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337:1029–1035

    Article  CAS  PubMed  Google Scholar 

  60. Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28

    Article  CAS  PubMed  Google Scholar 

  61. D’Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 116:1029–1034

    Article  PubMed  Google Scholar 

  62. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    Article  CAS  PubMed  Google Scholar 

  63. Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761–769

    Article  CAS  PubMed  Google Scholar 

  64. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549

    Article  CAS  PubMed  Google Scholar 

  65. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885

    Article  CAS  PubMed  Google Scholar 

  66. Hanauer SB (2003) Crohn’s disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 17:131–137

    Article  PubMed  Google Scholar 

  67. D’Haens G, Swijsen C, Noman M, Lemmens L, Ceuppens J, Agbahiwe H, Geboes K, Rutgeerts P (2001) Etanercept in the treatment of active refractory Crohn’s disease: a single-center pilot trial. Am J Gastroenterol 96:2564–2568

    Article  PubMed  Google Scholar 

  68. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088–1094

    Article  CAS  PubMed  Google Scholar 

  69. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR, CDP571 Crohn’s Disease Study Group (2001) An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120:1330–1338

    Article  CAS  PubMed  Google Scholar 

  70. Kupper TS (2004) Etanercept for Crohn’s disease. N Engl J Med 350:840

    CAS  Google Scholar 

  71. Akobeng AK, Zachos M (2004) Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev CD003574

    Google Scholar 

  72. Lin Z, Bai Y, Zheng P (2011) Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn’s disease. Eur J Gastroenterol Hepatol 23:1100–1110

    Article  CAS  PubMed  Google Scholar 

  73. Huang ML, Ran ZH, Shen J, Li XB, Xu XT, Xiao SD (2011) Efficacy and safety of adalimumab in Crohn’s disease: meta-analysis of placebo-controlled trials. J Dig Dis 12:165–172

    Article  PubMed  CAS  Google Scholar 

  74. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106:644–659

    Article  CAS  PubMed  Google Scholar 

  75. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ (2011) Review article: infliximab for Crohn’s disease treatment–shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 33:857–869

    Article  CAS  PubMed  Google Scholar 

  76. Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C (2011) A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess 15:1–244

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Loftus EV Jr, Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J (2011) Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn’s disease. Inflamm Bowel Dis 17:127–140

    Article  PubMed  Google Scholar 

  78. Jackson DY (2002) Alpha 4 integrin antagonists. Curr Pharm Des 8:1229–1253

    Article  CAS  PubMed  Google Scholar 

  79. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476

    Article  CAS  PubMed  Google Scholar 

  80. Goh L, Samanta A (2009) A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 29:1123–1135

    Article  CAS  PubMed  Google Scholar 

  81. van den Bosch F, Beaten D, Kruithof E, DeKeyser F, Mielants H, Veys EM (2001) Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis 60(suppl 3):iii33–iii36

    Google Scholar 

  82. Brandt J, Haibel H, Reddig J, Sieper J, Braun J (2002) Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29:118–122

    CAS  PubMed  Google Scholar 

  83. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM (2002) Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 61:207–212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193

    Article  CAS  PubMed  Google Scholar 

  85. Gorman JD, Sack KE, Davis JC (2000) Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebocontrolled study. Arthritis Rheum 43:S403

    Article  Google Scholar 

  86. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769

    Article  CAS  PubMed  Google Scholar 

  87. Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 61:171–173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. De La Mata J, Maese J, Martinez JA, Rosario P, Loza E (2011) Current evidence of the management of undifferentiated spondyloarthritis: a systematic literature review. Semin Arthritis Rheum 40:421–429

    Article  Google Scholar 

  89. Chaitow J, De Benedetti F, Brunner H et al (2010) Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER Trial. Ann Rheum Dis 69(suppl 3):146

    Google Scholar 

  90. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842–1847

    Article  CAS  PubMed  Google Scholar 

  91. Mease PJ (2002) Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61:298–304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390

    Article  CAS  PubMed  Google Scholar 

  93. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64:1035–1050

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Rodgers M., Epstein D., Bojke L., et al. (2011) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 15:i–xxi, 1–329

    Google Scholar 

  95. Saad AA, Symmons DP, Noyce PR, Ashcroft DM (2008) Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 35:883–890

    CAS  PubMed  Google Scholar 

  96. Pham T, Fautrel B, Dernis E et al (2007) Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 74:638–646

    Article  CAS  PubMed  Google Scholar 

  97. Doherty SD, van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, Foundation NP (2008) National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 59:209–217

    Article  PubMed  Google Scholar 

  98. Ellis CN, Krueger GG, Alefacept Clinical Study Group (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248–255

    Article  CAS  PubMed  Google Scholar 

  99. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS (2001) Etanercept combined with conventional treatment in Wegener’s granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 44:1149–1154

    Article  CAS  PubMed  Google Scholar 

  100. Ellman MH, MacDonald PA, Hayes FA (2000) Etanercept as treatment for diffuse scleroderma: a pilot study. Arthritis Rheum 43(Suppl.): S392

    Google Scholar 

  101. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44:1411–1415

    Article  CAS  PubMed  Google Scholar 

  102. Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, van Veldhuisen P, Sran P, Yaffe A, Goldman CK, Waldmann TA, Whitcup SM (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 96:7462–7466

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, Palace J, Sharrack B, Swingler R, Young C, Moseley IF, MacManus DG, Donoghue S, Miller DH (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53:466–472

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Immunogenetics, Center of Immunology and Transplantation, Immunobiology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Hellas, Greece

    Sotirios Kotsovilis

  2. Laboratory of Immunogenetics, Immunobiology Division, Center of Immunology and Transplantation, Biomedical Research Foundation of the Academy of Athens, Athens, Hellas, Greece

    Evangelos Andreakos

Authors
  1. Sotirios Kotsovilis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evangelos Andreakos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology, The Lautenberg Center, IMRIC The Hebrew University Hadassah Medical School, Jerusalem, Israel

    Michael Steinitz

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Kotsovilis, S., Andreakos, E. (2014). Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases. In: Steinitz, M. (eds) Human Monoclonal Antibodies. Methods in Molecular Biology, vol 1060. Humana, Totowa, NJ. https://doi.org/10.1007/978-1-62703-586-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-586-6_3

  • Published:

  • Publisher Name: Humana, Totowa, NJ

  • Print ISBN: 978-1-62703-585-9

  • Online ISBN: 978-1-62703-586-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation